DCM

DAFNA Capital Management Portfolio holdings

AUM $524M Turnover 22.92%
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+13.04%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$186M
AUM Growth
+$24.6M
Cap. Flow
+$12.5M
Cap. Flow %
6.76%
Top 10 Hldgs %
43.12%
Holding
83
New
10
Increased
18
Reduced
10
Closed
11
Avg Time Held
1.5 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.2 years

Top Buys

Rank Stock Value
1
VBIV icon
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
+$4.09M
2
ZGNX
Zogenix, Inc.
ZGNX
+$3.14M
3
LOXO
Loxo Oncology, Inc
LOXO
+$2.82M
4
SAGE icon
Sage Therapeutics
SAGE
+$2.79M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$2.06M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$1.85M
2
QURE icon
uniQure
QURE
+$1.68M
3
PODD icon
Insulet
PODD
+$1.64M
4
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$1.48M
5
ONC icon
BeOne Medicines Ltd
ONC
+$961K

Sector Composition

Rank Sector Weight
1 Healthcare 92.53%
2 Miscellaneous 7.1%
3 Financials 0.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$24.9M 13.42%
296,000
+33,879
+13% +$2.82M
2015 Q2
10 quarters
BPMC icon
2
DELISTED
Blueprint Medicines
BPMC
$7.59M 4.09%
100,691
+24,691
+32% +$1.74M
2016 Q4
4 quarters
ATRC icon
3
AtriCure
ATRC
$2.91B
$7.1M 3.82%
389,145
+5,000
+1% +$99K
2013 Q2
18 quarters
AERI
4
DELISTED
Aerie Pharmaceuticals
AERI
$6.98M 3.76%
116,770
– –
2014 Q3
13 quarters
ARGX icon
5
argenx
ARGX
$51.5B
$6.02M 3.24%
95,396
+55,396
+138% +$1.81M
2017 Q2
2 quarters
ONC icon
6
BeOne Medicines Ltd
ONC
$39.8B
$6M 3.23%
61,349
-10,500
-15% -$961K
2016 Q1
7 quarters
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.06B
$5.86M 3.16%
1,193,228
– –
2016 Q4
4 quarters
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$5.37M 2.89%
134,147
+81,647
+156% +$3.14M
2015 Q1
11 quarters
NXTM
9
DELISTED
NxStage Medical Inc.
NXTM
$5.24M 2.82%
216,119
– –
2013 Q2
18 quarters
ASND icon
10
Ascendis Pharma A/S
ASND
$14.9B
$4.99M 2.69%
124,639
+52,413
+73% +$1.91M
2015 Q1
11 quarters
IMMU
11
DELISTED
Immunomedics Inc
IMMU
$4.91M 2.65%
304,000
-156,451
-34% -$1.85M
2016 Q2
6 quarters
DXCM icon
12
DexCom
DXCM
$31.5B
$4.76M 2.57%
332,000
+102,000
+44% +$1.33M
2017 Q3
1 quarter
SAGE icon
13
DELISTED
Sage Therapeutics
SAGE
$4.74M 2.55%
+28,800
New +$2.79M
2017 Q4
0 quarters
VBIV icon
14
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$4.26M 2.29%
+33,267
New +$4.09M
2017 Q4
0 quarters
NBIX icon
15
Neurocrine Biosciences
NBIX
$13.8B
$4.23M 2.28%
54,508
– –
2016 Q1
7 quarters
ALDR
16
DELISTED
Alder Biopharmaceuticals
ALDR
$3.96M 2.13%
346,013
– –
2015 Q3
9 quarters
RIGL icon
17
Rigel Pharmaceuticals
RIGL
$875M
$3.82M 2.06%
98,348
+54,000
+122% +$2.06M
2017 Q1
3 quarters
LKFT icon
18
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
$3.71M 2%
39,609
+8,000
+25% +$757K
2015 Q3
9 quarters
CBAY icon
19
DELISTED
Cymabay Therapeutics
CBAY
$3.32M 1.79%
361,164
-73,836
-17% -$631K
2017 Q1
3 quarters
MGNX icon
20
MacroGenics
MGNX
$211M
$2.93M 1.58%
154,200
– –
2015 Q3
9 quarters
VIRX icon
21
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.89M 1.56%
22,371
-1,381
-6% -$129K
2016 Q4
4 quarters
IBB icon
22
iShares Biotechnology ETF
IBB
$10.4B
$2.79M 1.5%
26,100
– –
2016 Q4
4 quarters
ACHN
23
DELISTED
Achillion Pharmaceuticals
ACHN
$2.73M 1.47%
948,272
+230,000
+32% +$836K
2014 Q3
13 quarters
BEAT icon
24
DELISTED
BioTelemetry, Inc.
BEAT
$2.63M 1.42%
88,100
+38,100
+76% +$1.1M
2013 Q2
18 quarters
VYGR icon
25
Voyager Therapeutics
VYGR
$124M
$2.61M 1.4%
157,000
+39,741
+34% +$681K
2017 Q1
3 quarters
1
2 3

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, DAFNA Capital Management held 83 positions worth $186M, up 15% from $161M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

DAFNA Capital Management deployed $12.5M of net new capital in Q4 2017, opening 10 new positions and adding to 18 existing holdings. Its largest new stake was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 91% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $1.85M trimmed.

  • DAFNA Capital Management's largest Q4 2017 buy was VBI Vaccines, Inc. New Common Stock (Canada): 33,267 shares worth $4.26M.
  • DAFNA Capital Management added most to Zogenix, Inc. in Q4 2017, an estimated $3.14M increase.
  • DAFNA Capital Management's biggest Q4 2017 reduction was Immunomedics Inc, cutting an estimated $1.85M.
  • DAFNA Capital Management fully exited uniQure in Q4 2017, selling an estimated $1.68M.
  • DAFNA Capital Management's ten largest holdings make up 43% of its $186M portfolio in Q4 2017.
  • DAFNA Capital Management opened 10 new positions and closed 11 in Q4 2017.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $186M.

Based on DAFNA Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.